D. Fumagalli

发表

Transfer of clinically relevant gene expression signatures in breast cancer: from Affymetrix microarray to Illumina RNA-Sequencing technology

C. Sotiriou, C. Desmedt, D. Larsimont, 2014, BMC Genomics.

Genomic Characterization of Primary Invasive Lobular Breast Cancer.

P. Campbell, C. Sotiriou, F. Bertucci, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Serum thymidine kinase activity in patients with hormone receptor-positive and HER2-negative metastatic breast cancer treated with palbociclib and fulvestrant.

P. Neven, S. Loi, M. Piccart, 2022, European journal of cancer.

Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial.

S Michiels, C Desmedt, C Sotiriou, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Molecular Profiling: Moving Away from Tumor Philately

Jorge S. Reis-Filho, Christos Sotiriou, Debora Fumagalli, 2010, Science Translational Medicine.

Views – Research Highlights News & Views A time series evaluation of the in vivo effect of letrozole on gene expression in breast cancer

S. Michiels, D. Fumagalli, 2010 .

Estrogen receptor (ESR1) mRNA expression and benefit from tamoxifen in the treatment and prevention of estrogen receptor-positive breast cancer.

Debora Fumagalli, Norman Wolmark, Soonmyung Paik, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer in the APHINITY Trial: 6 Years' Follow-Up

R. Gelber, M. Piccart, G. Viale, 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Feasibility of developing reliable gene expression modules from FFPE derived RNA profiled on Affymetrix arrays

C. Sotiriou, S. Loi, S. Michiels, 2018, PloS one.

70-gene signature as an aid for treatment decisions in early breast cancer: updated results of the phase 3 randomised MINDACT trial with an exploratory analysis by age.

A. Glas, C. Sotiriou, M. Delorenzi, 2021, The Lancet. Oncology.

Predictive Biomarkers and Personalized Medicine MutationPro fi ling andMicrosatellite Instability in Stage II and III Colon Cancer : An Assessment of Their Prognostic and Oxaliplatin Predictive Value

N. Petrelli, S. Paik, Chungyeul Kim, 2012 .

Genomic grade adds prognostic value in invasive lobular carcinoma.

C. Sotiriou, F. Bertucci, C. Desmedt, 2013 .

Lucitanib for the Treatment of HR+/HER2− Metastatic Breast Cancer: Results from the Multicohort Phase II FINESSE Study

S. Loi, S. Loibl, F. André, 2019, Clinical Cancer Research.

Genomic hotspots but few recurrent fusion genes in breast cancer

C. Sotiriou, D. Larsimont, V. Detours, 2018, Genes, chromosomes & cancer.

Abstract GS1-04: Interim overall survival analysis of APHINITY (BIG 4-11): A randomized multicenter, double-blind, placebo-controlled trial comparing chemotherapy plus trastuzumab plus pertuzumab versus chemotherapy plus trastuzumab plus placebo as adjuvant therapy in patients with operable HER2-pos

R. Gelber, M. Piccart, G. Viale, 2020 .

Tumor PIK3CA Genotype and Prognosis in Early-Stage Breast Cancer: A Pooled Analysis of Individual Patient Data.

L. Saal, C. Sotiriou, S. Loi, 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

OlympiA: A randomized phase III trial of olaparib as adjuvant therapy in patients with high-risk HER2-negative breast cancer (BC) and a germline BRCA1/2 mutation (gBRCAm).

R. Gelber, A. Tutt, J. Garber, 2015 .

The 41-gene classifier TRAR predicts response of HER2 positive breast cancer patients in the NeoALTTO study.

M. Piccart, V. Torri, J. Baselga, 2018, European journal of cancer.

Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer.

R. Gelber, M. Piccart, S. Lakhani, 2021, The New England journal of medicine.

Patient-reported function, health-related quality of life, and symptoms in APHINITY: pertuzumab plus trastuzumab and chemotherapy in HER2-positive early breast cancer

R. Gelber, M. Piccart, J. Baselga, 2021, British Journal of Cancer.

Pharmacokinetics of pertuzumab administered concurrently with trastuzumab in Chinese patients with HER2-positive early breast cancer.

Yang Luo, Bing-he Xu, V. Tjan-Heijnen, 2019, Anti-cancer drugs.

Circulating Tumor DNA in HER2-Ampli ﬁ ed Breast Cancer: A Translational Research Substudy of the NeoALTTO Phase III Trial

C. Sotiriou, S. Loi, M. Piccart, 2019 .

OlympiA: A phase III, multicenter, randomized, placebo-controlled trial of adjuvant olaparib after (neo)adjuvant chemotherapy in patients with germline BRCA1/2 mutations and high-risk HER2-negative early breast cancer.

R. Gelber, A. Tutt, S. Lakhani, 2021 .

Tumor PIK3CA Genotype and Prognosis in Early-Stage Breast Cancer: A Pooled Analysis of Individual Patient Data.

L. Saal, C. Sotiriou, S. Loi, 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Impact of Diabetes, Insulin, and Metformin Use on the Outcome of Patients With Human Epidermal Growth Factor Receptor 2-Positive Primary Breast Cancer: Analysis From the ALTTO Phase III Randomized Trial.

L. Harris, A. Wolff, M. Piccart-Gebhart, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

RNA Sequencing to Predict Response to Neoadjuvant Anti-HER2 Therapy: A Secondary Analysis of the NeoALTTO Randomized Clinical Trial

C. Sotiriou, S. Loi, M. Piccart, 2017, JAMA oncology.

Loss of ARID1A Activates ANXA1, which Serves as a Predictive Biomarker for Trastuzumab Resistance

G. Mills, R. Bernards, C. Sotiriou, 2016, Clinical Cancer Research.

PIK3CA mutations are associated with decreased benefit to neoadjuvant human epidermal growth factor receptor 2-targeted therapies in breast cancer.

R. Bernards, N. Schultz, C. Sotiriou, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Somatic Mutation Profiling and Associations With Prognosis and Trastuzumab Benefit in Early Breast Cancer

C. Sotiriou, S. Loi, M. Piccart, 2013, Journal of the National Cancer Institute.

Phosphatidylinositol 3-kinase/AKT/mammalian target of rapamycin pathway inhibition: a breakthrough in the management of luminal (ER+/HER2−) breast cancers?

S. Loi, D. Zardavas, D. Fumagalli, 2012, Current opinion in oncology.

Post-neoadjuvant treatment and the management of residual disease in breast cancer: state of the art and perspectives

M. Piccart, D. Fumagalli, E. de Azambuja, 2019, Therapeutic advances in medical oncology.

Genomic and Transcriptomic Analyses of Breast Cancer Primaries and Matched Metastases in AURORA, the Breast International Group (BIG) Molecular Screening Initiative

R. Greil, C. Sotiriou, S. Loi, 2021, Cancer discovery.

Is the differentiation into molecular subtypes of breast cancer important for staging, local and systemic therapy, and follow up?

C. Sotiriou, M. Piccart, D. Fumagalli, 2014, Cancer treatment reviews.

Plasma circulating tumor DNA as an alternative to metastatic biopsies for mutational analysis in breast cancer.

S Michiels, C Sotiriou, C. Sotiriou, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

A rapid, sensitive, reproducible and cost-effective method for mutation profiling of colon cancer and metastatic lymph nodes

S. Paik, K. Pogue-Geile, D. Fumagalli, 2010, BMC Cancer.

The AURORA initiative for metastatic breast cancer

C Sotiriou, C. Sotiriou, M. Dowsett, 2014, British Journal of Cancer.

Deciphering clonality in aneuploid breast tumors using SNP array and sequencing data

T. Speed, C. Sotiriou, P. Neven, 2014, Genome Biology.

Copy Number Aberration Analysis to Predict Response to Neoadjuvant Anti-HER2 Therapy: Results from the NeoALTTO Phase III Clinical Trial

C. Sotiriou, S. Loi, M. Piccart, 2021, Clinical Cancer Research.

The AURORA pilot study for molecular screening of patients with advanced breast cancer–a study of the breast international group

P. Campbell, C. Sotiriou, S. Loi, 2017, npj Breast Cancer.

Unravelling the epigenomic dimension of breast cancers

D. Fumagalli, F. Fuks, S. Dedeurwaerder, 2011, Current opinion in oncology.

The Prognostic Role of Androgen Receptor in Patients with Early-Stage Breast Cancer: A Meta-analysis of Clinical and Gene Expression Data

C. Sotiriou, M. Piccart, D. Zardavas, 2016, Clinical Cancer Research.

Molecular biology in breast cancer: should molecular classifiers be assessed by conventional tools or by gene expression arrays?

C. Sotiriou, C. Desmedt, F. André, 2012, Critical reviews in oncology/hematology.

Luminal B breast cancer: molecular characterization, clinical management, and future perspectives.

Christos Sotiriou, Debora Fumagalli, C. Sotiriou, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Integrative proteomic and gene expression analysis identify potential biomarkers for adjuvant trastuzumab resistance: analysis from the Fin-her phase III randomized trial

C. Sotiriou, P. Neven, S. Loi, 2015, Oncotarget.

Mutation Profiling and Microsatellite Instability in Stage II and III Colon Cancer: An Assessment of Their Prognostic and Oxaliplatin Predictive Value

Greg Yothers, Hyun Joo Choi, Debora Fumagalli, 2012, Clinical Cancer Research.

No significant viral transcription detected in whole breast cancer transcriptomes

David Gacquer, Christos Sotiriou, Debora Fumagalli, 2015, BMC Cancer.

Survival outcomes of the NeoALTTO study (BIG 1-06): updated results of a randomised multicenter phase III neoadjuvant clinical trial in patients with HER2-positive primary breast cancer.

R. Gelber, J. Baselga, T. Hickish, 2019, European journal of cancer.

Adjuvant Anti-HER2 Therapy, Treatment-Related Amenorrhea, and Survival in Premenopausal HER2-Positive Early Breast Cancer Patients

R. Gelber, M. Piccart, J. Baselga, 2018, Journal of the National Cancer Institute.

Somatic mutation, copy number and transcriptomic profiles of primary and matched metastatic estrogen receptor-positive breast cancers.

C. Sotiriou, S. Loi, D. Larsimont, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

Tamoxifen in early-stage estrogen receptor-positive breast cancer: overview of clinical use and molecular biomarkers for patient selection

S. Loi, C. Criscitiello, D. Fumagalli, 2010, OncoTargets and therapy.

Principles Governing A-to-I RNA Editing in the Breast Cancer Transcriptome

David Gacquer, Peter J. Campbell, Christine Desmedt, 2015, bioRxiv.

Strategies to Incorporate Translational Research Science into Clinical Trials in Breast Cancer

C. Sotiriou, C. Desmedt, M. Piccart, 2010 .

A common language in neoadjuvant breast cancer clinical trials: proposals for standard definitions and endpoints.

M. Ellis, L. Esserman, N. Hylton, 2012, The Lancet. Oncology.

Palbociclib with adjuvant endocrine therapy in early breast cancer (PALLAS): interim analysis of a multicentre, open-label, randomised, phase 3 study.

E. Winer, P. Morris, H. Rugo, 2021, The Lancet. Oncology.

LBA12 PALLAS: A randomized phase III trial of adjuvant palbociclib with endocrine therapy versus endocrine therapy alone for HR+/HER2- early breast cancer

M. Gnant, H. Burstein, S. Loibl, 2020 .

Association of T-Cell Receptor Repertoire Use With Response to Combined Trastuzumab-Lapatinib Treatment of HER2-Positive Breast Cancer: Secondary Analysis of the NeoALTTO Randomized Clinical Trial

O. Elemento, C. Sotiriou, S. Loi, 2018, JAMA oncology.

Association between SPARC mRNA Expression, Prognosis and Response to Neoadjuvant Chemotherapy in Early Breast Cancer: A Pooled in-silico Analysis

C. Sotiriou, C. Desmedt, D. Larsimont, 2013, PloS one.

Genomic grade adds prognostic value in invasive lobular carcinoma.

S Michiels, C Desmedt, C Sotiriou, 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

Gene profiling assay and application: the predictive role in primary therapy.

C. Sotiriou, S. Loi, C. Desmedt, 2011, Journal of the National Cancer Institute. Monographs.

Treatment of pT1N0 breast cancer: multigene predictors to assess risk of relapse.

C. Sotiriou, D. Fumagalli, 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

Molecular Testing in Breast Cancer

C. Sotiriou, D. Zardavas, D. Fumagalli, 2014 .

Deciphering clonality in aneuploid breast tumors using SNP array and sequencing data

T. Speed, C. Sotiriou, P. Neven, 2014, Genome Biology.

Proposals for uniform collection of biospecimens from neoadjuvant breast cancer clinical trials: timing and specimen types.

L. Esserman, J. Forbes, S. Loi, 2011, The Lancet. Oncology.

Assessment of the management of carcinomatous meningitis from breast cancer globally: a study by the Breast International Group Brain Metastasis Task Force

H. Tesch, S. Aebi, D. Fumagalli, 2022, ESMO open.

Predicting degree of benefit from adjuvant trastuzumab in NSABP trial B-31.

Jong-Hyeon Jeong, Hanna Bandos, Debora Fumagalli, 2013, Journal of the National Cancer Institute.

The prognostic and predictive value of gene expression signatures in breast cancer

C. Sotiriou, D. Fumagalli, H. Azim, 2011 .

216TiPOlympiA: A randomized phase III trial of olaparib as adjuvant therapy in patients with high-risk HER2-negative breast cancer (BC) and a germline BRCA1/2 mutation (gBRCAm)

R. Gelber, A. Tutt, J. Garber, 2017 .

Copy number aberration analysis to predict response to neoadjuvant anti-HER2 therapy: Results from the NeoALTTO phase III trial

C. Sotiriou, S. Loi, J. Baselga, 2017 .

Tumor Cellularity and Infiltrating Lymphocytes (CelTIL) as a Survival Surrogate in HER2-Positive Breast Cancer.

S. Loi, R. Salgado, P. Nuciforo, 2021, Journal of the National Cancer Institute.

Tumor-infiltrating lymphocytes in patients with HER2-positive breast cancer treated with neoadjuvant chemotherapy plus trastuzumab, lapatinib or their combination: A meta-analysis of randomized controlled trials.

C. Sotiriou, R. Salgado, C. Solinas, 2017, Cancer treatment reviews.

Cardiac biomarkers for early detection and prediction of trastuzumab and/or lapatinib-induced cardiotoxicity in patients with HER2-positive early-stage breast cancer: a NeoALTTO sub-study (BIG 1-06)

M. Piccart, L. Pusztai, Dar-Ren Chen, 2017, Breast Cancer Research and Treatment.

Constitutive phosphorylated STAT3-associated gene signature is predictive for trastuzumab resistance in primary HER2-positive breast cancer

C. Sotiriou, P. Neven, S. Loi, 2015, BMC Medicine.

Uncovering the genomic heterogeneity of multifocal breast cancer

D. Amadori, P. Campbell, C. Sotiriou, 2015, The Journal of pathology.

ALEXANDRA/IMpassion030: A phase III study of standard adjuvant chemotherapy with or without atezolizumab in early-stage triple-negative breast cancer.

R. Gelber, M. Piccart, G. Viale, 2019, Journal of Clinical Oncology.

Integrated Molecular and Immune Phenotype of HER2-Positive Breast Cancer and Response to Neoadjuvant Therapy: A NeoALTTO Exploratory Analysis

C. Sotiriou, M. Piccart, M. Colombo, 2021, Clinical Cancer Research.

P1-02-05: Invasive Lobular Carcinoma – A Luminal Breast Cancer Histotype Enriched for Epithelial-to-Mesenchymal Transition Features.

C. Sotiriou, F. Bertucci, D. Larsimont, 2011 .

The footprint of the ageing stroma in older patients with breast cancer

C. Sotiriou, P. Neven, D. Lambrechts, 2017, Breast Cancer Research.

Circulating Tumor DNA in HER2-Amplified Breast Cancer: A Translational Research Substudy of the NeoALTTO Phase III Trial

C. Sotiriou, S. Loi, M. Piccart, 2019, Clinical Cancer Research.

The use of breast imaging for predicting response to neoadjuvant lapatinib, trastuzumab and their combination in HER2-positive breast cancer: Results from Neo-ALTTO.

J. Baselga, B. Naume, C. Criscitiello, 2018, European journal of cancer.

Updated results from the international phase III ALTTO trial (BIG 2-06/Alliance N063D).

R. Gelber, J. Baselga, Z. Aziz, 2021, European journal of cancer.

Six-year absolute invasive disease-free survival benefit of adding adjuvant pertuzumab to trastuzumab and chemotherapy for patients with early HER2-positive breast cancer: A Subpopulation Treatment Effect Pattern Plot (STEPP) analysis of the APHINITY (BIG 4-11) trial.

R. Gelber, S. Loi, F. Cardoso, 2022, European journal of cancer.

The AURORA pilot study for molecular screening of patients with advanced breast cancer–a study of the breast international group

P. Campbell, C. Sotiriou, S. Loi, 2017, npj Breast Cancer.

Genomic correlates of response to adjuvant trastuzumab (H) and pertuzumab (P) in HER2+ breast cancer (BC): Biomarker analysis of the APHINITY trial.

S. Loi, M. Piccart, C. Denkert, 2019, Journal of Clinical Oncology.

The footprint of the ageing stroma in older patients with breast cancer

C. Sotiriou, P. Neven, D. Lambrechts, 2017, Breast Cancer Research.

Immune Checkpoint Blockade in HER2-Positive Breast Cancer: What Role in Early Disease Setting?

C. Solinas, M. Dieci, D. Fumagalli, 2021, Cancers.

Abstract CT135: Uncovering the genomic heterogeneity of multifocal breast cancer

D. Amadori, P. Campbell, C. Sotiriou, 2015 .

New Strategies in Breast Cancer: The Significance of Molecular Subtypes in Systemic Adjuvant Treatment for Small T1a,bN0M0 Tumors

C. Sotiriou, M. Piccart, D. Fumagalli, 2014, Clinical Cancer Research.

CCR New Strategies New Strategies in Breast Cancer : The Signi fi cance of Molecular Subtypes in Systemic Adjuvant Treatment for Small T 1 a , bN 0 M 0 Tumors

C. Sotiriou, M. Piccart, D. Fumagalli, 2014 .

Are we assuming too much with our statistical assumptions? Lessons learned from the ALTTO Trial.

R. Gelber, J. Baselga, M. Piccart-Gebhart, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

Pharmacokinetic and exploratory exposure–response analysis of pertuzumab in patients with operable HER2-positive early breast cancer in the APHINITY study

J. Baselga, G. von Minckwitz, D. Fumagalli, 2019, Cancer Chemotherapy and Pharmacology.

Tumor PIK3CA mutations, lymphocyte infiltration, and recurrence-free survival (RFS) in early breast cancer (BC): Results from the FinHER trial.

C. Sotiriou, S. Loi, D. Larsimont, 2012 .

Are we assuming too much with our statistical assumptions? Lessons learned from the ALTTO trial.

R. Gelber, J. Baselga, M. Piccart-Gebhart, 2019 .

Effect of body mass index on response to neo-adjuvant therapy in HER2-positive breast cancer: an exploratory analysis of the NeoALTTO trial

M. Piccart, M. Daidone, J. Huober, 2020, Breast cancer research : BCR.

Survival outcomes of the NeoALTTO study: Updated results of a randomized multicenter phase III neoadjuvant trial.

R. Gelber, J. Baselga, Bing-he Xu, 2017 .

CD44+ CD24-/low phenotype and resistance to trastuzumab in HER2-positive breast cancer cell lines.

C. Sotiriou, S. Michiels, D. Fumagalli, 2011, Pharmacogenomics.

Abstract PD3-01: BluePrint performance in predicting pertuzumab benefit in genomically HER2-positive patients: A biomarker analysis of the APHINITY trial

R. Bernards, R. Gelber, S. Loi, 2021 .

Abstract GS1-04: Copy number aberration analysis to predict response to neoadjuvant anti-HER2 therapy: Results from the NeoALTTO phase III trial

C. Sotiriou, S. Loi, M. Piccart, 2018 .

The prognostic and predictive value of gene expression signatures in breast cancer

C. Sotiriou, D. Fumagalli, H. Azim, 2011 .

Abstract P6-07-22: Association between SPARC mRNA expression, prognosis and response to neoadjuvant chemotherapy in early breast cancer (BC): a pooledin-silicoanalysis

C. Sotiriou, C. Desmedt, M. Piccart, 2012 .

Elucidating the biological basis of prognosis in young women with early breast cancer (BC) using gene expression profiling.

C. Sotiriou, S. Loi, B. Haibe-Kains, 2011, Journal of Clinical Oncology.

ALEXANDRA/IMpassion030: A phase 3 study of standard adjuvant chemotherapy with or without atezolizumab in patients with early-stage triple-negative breast cancer.

E. Winer, R. Gelber, G. Viale, 2021 .

Abstract S1-05: Tumor infiltrating lymphocytes (TILs) indicate trastuzumab benefit in early-stage HER2-positive breast cancer (HER2+ BC)

C. Sotiriou, S. Loi, C. Desmedt, 2013 .

An ideal prognostic test for estrogen receptor-positive breast cancer?

S. Paik, D. Fumagalli, G. Tang, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Patient (pt)-reported function and symptoms in APHINITY: A randomized comparison of chemotherapy (C) + trastuzumab (H) + placebo (Pla) versus C + H + pertuzumab (P) as adjuvant therapy in pts with HER2-positive early breast cancer (EBC).

R. Gelber, J. Baselga, G. Viale, 2018 .

Validation of the NSABP/NRG Oncology 8-Gene Trastuzumab-benefit Signature in Alliance/NCCTG N9831

D. Serie, E. Thompson, S. Paik, 2020, JNCI cancer spectrum.

Mutation Profiling and Microsatellite Instability in Stage II and III Colon Cancer: An Assessment of Their Prognostic and Oxaliplatin Predictive Value

N. Petrelli, S. Paik, Chungyeul Kim, 2012, Clinical Cancer Research.

PIK3CA mutations are associated with decreased benefit to neoadjuvant human epidermal growth factor receptor 2-targeted therapies in breast cancer.

R. Bernards, N. Schultz, C. Sotiriou, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Proposals for uniform collection of biospecimens from neoadjuvant breast cancer clinical trials: timing and specimen types.

L. Esserman, J. Forbes, S. Loi, 2011, The Lancet. Oncology.

Genomic grade adds prognostic value in invasive lobular carcinoma.

C. Sotiriou, F. Bertucci, D. Birnbaum, 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

New Strategies in Breast Cancer: The Significance of Molecular Subtypes in Systemic Adjuvant Treatment for Small T1a,bN0M0 Tumors

C. Sotiriou, M. Piccart, D. Fumagalli, 2014, Clinical Cancer Research.

C. Sotiriou, R. Salgado, C. Solinas, 2017, Cancer treatment reviews.

Correction: Association between SPARC mRNA Expression, Prognosis and Response to Neoadjuvant Chemotherapy in Early Breast Cancer: A Pooled in-silico Analysis

C. Sotiriou, C. Desmedt, D. Larsimont, 2013, PLoS ONE.